Exact Sciences Presents Clinical Validation of Oncodetect® Test for Triple Negative Breast Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 24 2025
0mins
Source: Newsfilter
- Clinical Validation Results: Exact Sciences will present the first clinical validation of the Oncodetect® test for triple-negative breast cancer at the 2025 San Antonio Breast Cancer Symposium, indicating its high sensitivity in molecular residual disease detection, which could significantly enhance patient monitoring and prognosis.
- Economic Impact Analysis: The utilization of the Oncotype DX Breast Recurrence Score test has been shown to improve outcomes and reduce healthcare costs across diverse racial and ethnic groups in the U.S., highlighting its potential value in promoting equity in breast cancer care.
- Large-Scale Research Initiative: The NSABP-B59/GBG-96-GeparDouze trial, in collaboration with the National Surgical Adjuvant Breast and Bowel Project, is enrolling over 1,800 participants, with multiple data readouts expected in 2027 to further support the clinical evidence for the Oncodetect test.
- International Application Expansion: The first large-scale study of the Oncotype DX test in Japan confirms its applicability in HR+/HER2- early breast cancer patients, demonstrating its broad potential for use in international settings.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
